Sunshine Biopharma Inc. (SBFM) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Sunshine Biopharma Inc. on December 11, 2025. The Company is incorporated in Colorado and trades on The Nasdaq Stock Market LLC under the symbols SBFM (Common Stock) and SBFMW (Warrants).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Three primary matters were submitted to a vote of security holders:
- Election of Directors: Five directors were elected to serve until the next annual meeting. All candidates received overwhelming support with over 130 million votes "For" each.
- Ratification of Auditors: Stockholders ratified the appointment of M&K CPAS, PLLC as the independent registered public accounting firm for 2025.
- Equity Plan Amendment: Stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing the authorized shares for issuance to 683,000.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, or contingencies beyond the standard disclosure of the voting results.
Investor Verification Checklist
- Verify the impact of the increased equity pool (683,000 shares) on potential future dilution.
- Confirm the tenure and background of the newly elected directors (Dr. Steve N. Slilaty, Mr. Camille Sebaaly, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller).
- Review the Company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.